198 related articles for article (PubMed ID: 1378696)
1. An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma.
Fuchs U; Kivelä T; Summanen P; Immonen I; Tarkkanen A
Am J Pathol; 1992 Jul; 141(1):169-81. PubMed ID: 1378696
[TBL] [Abstract][Full Text] [Related]
2. PC-10 as a predictor of prognosis after antigen retrieval in posterior uveal melanoma.
Seregard S; Oskarsson M; Spångberg B
Invest Ophthalmol Vis Sci; 1996 Jun; 37(7):1451-8. PubMed ID: 8641848
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin positivity in paraffin-embedded malignant melanomas: comparative study of KL1, A4 and Lu5 antibodies.
Korabiowska M; Fischer G; Steinacker A; Stachura J; Cordon-Cardo C; Brinck U
Anticancer Res; 2004; 24(5B):3203-7. PubMed ID: 15510611
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma?
Väisänen A; Kallioinen M; von Dickhoff K; Laatikainen L; Höyhtyä M; Turpeenniemi-Hujanen T
J Pathol; 1999 May; 188(1):56-62. PubMed ID: 10398141
[TBL] [Abstract][Full Text] [Related]
5. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.
Blom DJ; Luyten GP; Mooy C; Kerkvliet S; Zwinderman AH; Jager MJ
Invest Ophthalmol Vis Sci; 1997 Aug; 38(9):1865-72. PubMed ID: 9286277
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
7. HLA expression in choroidal melanomas: correlation with clinicopathological features.
Krishnakumar S; Abhyankar D; Lakshmi SA; Pushparaj V; Shanmugam MP; Biswas J
Curr Eye Res; 2004 Jun; 28(6):409-16. PubMed ID: 15512948
[TBL] [Abstract][Full Text] [Related]
8. Anomalous cytokeratin expression in malignant melanoma: one- and two-dimensional western blot analysis and immunohistochemical survey of 100 melanomas.
Zarbo RJ; Gown AM; Nagle RB; Visscher DW; Crissman JD
Mod Pathol; 1990 Jul; 3(4):494-501. PubMed ID: 1699224
[TBL] [Abstract][Full Text] [Related]
9. Expression of epidermal growth factor receptor: risk factor in uveal melanoma.
Hurks HM; Metzelaar-Blok JA; Barthen ER; Zwinderman AH; De Wolff-Rouendaal D; Keunen JE; Jager MJ
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2023-7. PubMed ID: 10892838
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical spectrum of malignant melanoma. The common presence of keratins.
Miettinen M; Franssila K
Lab Invest; 1989 Dec; 61(6):623-8. PubMed ID: 2481151
[TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.
Khatib N; Pe'er J; Ortenberg R; Schachter J; Frenkel S; Markel G; Amer R
Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9368-72. PubMed ID: 22039239
[TBL] [Abstract][Full Text] [Related]
12. S100 immunophenotypes of uveal melanomas.
Kan-Mitchell J; Rao N; Albert DM; Van Eldik LJ; Taylor CR
Invest Ophthalmol Vis Sci; 1990 Aug; 31(8):1492-6. PubMed ID: 1696942
[TBL] [Abstract][Full Text] [Related]
13. Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss.
Coupland SE; Vorum H; Mandal N; Kalirai H; Honoré B; Urbak SF; Lake SL; Dopierala J; Damato B
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):12-20. PubMed ID: 19643972
[TBL] [Abstract][Full Text] [Related]
14. Expression of vascular endothelial growth factor a, matrix metalloproteinase 9 and extravascular matrix patterns in iris and ciliary body melanomas.
Sahin A; Kiratli H; Tezel GG; Soylemezoglu F; Bilgic S
Ophthalmic Res; 2007; 39(1):40-4. PubMed ID: 17164576
[TBL] [Abstract][Full Text] [Related]
15. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin immunoreactivity in malignant fibrous histiocytoma and spindle cell tumors: comparison between frozen and paraffin-embedded tissues.
Litzky LA; Brooks JJ
Mod Pathol; 1992 Jan; 5(1):30-4. PubMed ID: 1371872
[TBL] [Abstract][Full Text] [Related]
17. Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers.
Hendrix MJ; Seftor EA; Seftor RE; Gardner LM; Boldt HC; Meyer M; Pe'er J; Folberg R
Lab Invest; 1998 Feb; 78(2):153-63. PubMed ID: 9484713
[TBL] [Abstract][Full Text] [Related]
18. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
19. Possible implications of MCAM expression in metastasis and non-metastatic of primary uveal melanoma patients.
Beutel J; Wegner J; Wegner R; Ziemssen F; Nassar K; Rohrbach JM; Hilgers RD; Lüke M; Grisanti S
Curr Eye Res; 2009 Nov; 34(11):1004-9. PubMed ID: 19958117
[TBL] [Abstract][Full Text] [Related]
20. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma.
El-Shabrawi Y; Ardjomand N; Radner H; Ardjomand N
J Pathol; 2001 Jun; 194(2):201-6. PubMed ID: 11400149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
